Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) VP Sells $36,795.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 500 shares of the company’s stock in a transaction that occurred on Tuesday, October 13th. The shares were sold at an average price of $73.59, for a total value of $36,795.00. Following the completion of the transaction, the vice president owned 73,424 shares in the company, valued at approximately $5,403,272.16. The trade was a 0.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Meredith Cook also recently made the following trade(s):

• On Monday, September 14th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $70.79, for a total value of $35,395.00.
• On Thursday, August 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $75.48, for a total value of $37,740.00.

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP opened at $72.28 on Friday. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41. The business has a fifty day simple moving average of $73.71 and a two-hundred day simple moving average of $78.01. ANI Pharmaceuticals, Inc. has a 1 year low of $69.58 and a 1 year high of $97.00. The company has a market capitalization of $1.66 billion, a P/E ratio of 15.58, a P/E/G ratio of 2.26 and a beta of 0.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.04 by $0.17. The firm had revenue of $266.04 million for the quarter, compared to analyst estimates of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%. The business’s revenue was up 25.8% on a year-over-year basis. During the same period in the previous year, the company posted $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, analysts expect that ANI Pharmaceuticals, Inc. will post 7.76 earnings per share for the current year.

Institutional Investors Weigh In On ANI Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company boosted its holdings in shares of ANI Pharmaceuticals by 1.5% in the first quarter. The Manufacturers Life Insurance Company now owns 9,577 shares of the specialty pharmaceutical company’s stock worth $736,000 after acquiring an additional 143 shares during the period. GAMMA Investing LLC grew its position in shares of ANI Pharmaceuticals by 13.4% in the third quarter. GAMMA Investing LLC now owns 1,783 shares of the specialty pharmaceutical company’s stock valued at $130,000 after purchasing an additional 211 shares in the last quarter. Versant Capital Management Inc grew its position in shares of ANI Pharmaceuticals by 103.3% in the third quarter. Versant Capital Management Inc now owns 427 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 217 shares in the last quarter. New York State Teachers Retirement System raised its stake in shares of ANI Pharmaceuticals by 1.6% during the 1st quarter. New York State Teachers Retirement System now owns 23,268 shares of the specialty pharmaceutical company’s stock valued at $1,789,000 after purchasing an additional 356 shares during the period. Finally, KBC Group NV bought a new stake in shares of ANI Pharmaceuticals during the 1st quarter valued at $28,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on ANIP shares. Guggenheim dropped their price objective on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a report on Monday, August 10th. Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, September 9th. They set an “outperform” rating and a $104.00 target price for the company. Oppenheimer started coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, September 23rd. They issued a “market perform” rating and a $85.00 target price for the company. Wall Street Zen downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings lowered shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Three analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $99.60.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes branded and generic prescription medicines. The company focuses on products with complex formulations, difficult-to-manufacture dosage forms and limited competition, serving therapeutic areas that include rare diseases, ophthalmology, endocrinology, central nervous system conditions and other specialty markets.

ANI’s portfolio includes Cortrophin Gel (repository corticotropin injection), a specialty therapy used for certain inflammatory and autoimmune conditions, as well as a range of established brand and generic products.